http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011051423-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d3314dfc95c459205e159d14df12cb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27a71ddaaa2f5a8c228fc6cb3f3b3098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cca27d6d45fa919bd1af085abda52e2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de0f30d1aaee9eac11f889d09c530c05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d1623a9f74f8c25752b0db74106de31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_205f1aa86d075d5bc1b2aa59e956c420 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate | 2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1195102f1549d815658d687beaa10022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d2bdc57aa258ff34c0219190a20e57a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bbe25d0054a67b3e70d7fc0abb31d7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42feeeb28672e2c7e9edca7d6d0c8341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149f5458756be2a9125c06869712bbd6 |
| publicationDate | 2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2011051423-A1 |
| titleOfInvention | Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy |
| abstract | The present invention relates to the use of 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro- 1 H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone (Formula (I)) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of dementia and/or a neurodegenerative disease (e.g. Alzheimer's disease, in particular cognitive impairment therein), schizophrenia (e.g. cognitive impairment associated therewith), attention deficit hyperactivity disorder, somnolence, or epilepsy, in a human, by oral administration to the human using an escalating dosage regimen comprising: - an initial dosage regimen of from 2 to 15 micrograms (preferably from 5 to 10 micrograms) of the 1 -{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3-benzazepin-7- yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day, and subsequently - a maintenance dosage regimen of from 30 to 150 micrograms (preferably from from 40 to 80 micrograms) of the 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1 H-3- benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone or the pharmaceutically acceptable salt thereof (measured as the free base), administered orally once per day. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9789102-B2 |
| priorityDate | 2009-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.